224 related articles for article (PubMed ID: 21080243)
1. The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.
Horwitz SM
Curr Hematol Malig Rep; 2011 Mar; 6(1):67-72. PubMed ID: 21080243
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors: novel agents in cancer treatment.
Glass E; Viale PH
Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
Kitadate A; Ikeda S; Abe F; Takahashi N; Shimizu N; Matsue K; Tagawa H
Haematologica; 2018 Jan; 103(1):126-135. PubMed ID: 29025909
[TBL] [Abstract][Full Text] [Related]
4. The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
Hymes KB
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):98-109. PubMed ID: 20371442
[TBL] [Abstract][Full Text] [Related]
5. Use of class I histone deacetylase inhibitor romidepsin in combination regimens.
Petrich A; Nabhan C
Leuk Lymphoma; 2016 Aug; 57(8):1755-65. PubMed ID: 27118119
[TBL] [Abstract][Full Text] [Related]
6. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
Zain J; O'Connor OA
Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S58-78. PubMed ID: 21132350
[TBL] [Abstract][Full Text] [Related]
7. [Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors].
Zirlik K; Nashan D; Veelken H
Pharm Unserer Zeit; 2010 May; 39(3):190-6. PubMed ID: 20425773
[No Abstract] [Full Text] [Related]
8. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
Rangwala S; Zhang C; Duvic M
Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
[TBL] [Abstract][Full Text] [Related]
9. New drug therapies in peripheral T-cell lymphoma.
Howman RA; Prince HM
Expert Rev Anticancer Ther; 2011 Mar; 11(3):457-72. PubMed ID: 21417858
[TBL] [Abstract][Full Text] [Related]
10. Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL).
Lu G; Jin S; Lin S; Gong Y; Zhang L; Yang J; Mou W; Du J
Clin Epigenetics; 2023 Aug; 15(1):124. PubMed ID: 37533111
[TBL] [Abstract][Full Text] [Related]
11. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.
Bates SE; Zhan Z; Steadman K; Obrzut T; Luchenko V; Frye R; Robey RW; Turner M; Gardner ER; Figg WD; Steinberg SM; Ling A; Fojo T; To KW; Piekarz RL
Br J Haematol; 2010 Jan; 148(2):256-67. PubMed ID: 19874311
[TBL] [Abstract][Full Text] [Related]
12. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
Duvic M
Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
[TBL] [Abstract][Full Text] [Related]
14. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.
Ma H; O'Connor OA; Marchi E
Expert Rev Hematol; 2019 Mar; 12(3):137-146. PubMed ID: 30782038
[TBL] [Abstract][Full Text] [Related]
15. Emerging role of epigenetic therapies in cutaneous T-cell lymphomas.
Zain J; Kaminetzky D; O'Connor OA
Expert Rev Hematol; 2010 Apr; 3(2):187-203. PubMed ID: 21083462
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.
Jain N; Odenike O
Expert Opin Pharmacother; 2010 Dec; 11(18):3073-84. PubMed ID: 21080855
[TBL] [Abstract][Full Text] [Related]
17. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
Watanabe T
Expert Opin Investig Drugs; 2010 Sep; 19(9):1113-27. PubMed ID: 20649502
[TBL] [Abstract][Full Text] [Related]
18. T time: Emerging and new therapies for peripheral T-cell lymphoma.
Mina A; Pro B
Blood Rev; 2022 Mar; 52():100889. PubMed ID: 34716031
[TBL] [Abstract][Full Text] [Related]
19. Novel therapies in peripheral T-cell lymphomas.
O'Leary HM; Savage KJ
Curr Hematol Malig Rep; 2008 Oct; 3(4):213-20. PubMed ID: 20425468
[TBL] [Abstract][Full Text] [Related]
20. From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas and Plasma Cell Myeloma.
Mihaila RG
Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):283-295. PubMed ID: 28933264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
